EA200000039A1 - Лечение диабета тиазолидиндионом и сульфонилмочевиной - Google Patents

Лечение диабета тиазолидиндионом и сульфонилмочевиной

Info

Publication number
EA200000039A1
EA200000039A1 EA200000039A EA200000039A EA200000039A1 EA 200000039 A1 EA200000039 A1 EA 200000039A1 EA 200000039 A EA200000039 A EA 200000039A EA 200000039 A EA200000039 A EA 200000039A EA 200000039 A1 EA200000039 A1 EA 200000039A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
thiazolidindion
uride
sulphonyl
treatment
Prior art date
Application number
EA200000039A
Other languages
English (en)
Other versions
EA003025B1 (ru
Inventor
Стефен Элистэр Смит
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200000039A1 publication Critical patent/EA200000039A1/ru
Publication of EA003025B1 publication Critical patent/EA003025B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Способ лечения сахарного диабета и состояний, ассоциированных с сахарным диабетом, у млекопитающего, где способ включает введение эффективного нетоксичного и фармацевтически приемлемого количества инсулин-сенсибилизирующего вещества и средства, стимулирующего секрецию инсулина, млекопитающему, нуждающемуся в этом.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000039A 1997-06-18 1998-06-15 Лечение диабета тиазолидиндионом и сульфонилмочевиной EA003025B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003688 WO1998057649A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and sulphonylurea

Publications (2)

Publication Number Publication Date
EA200000039A1 true EA200000039A1 (ru) 2000-08-28
EA003025B1 EA003025B1 (ru) 2002-12-26

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000039A EA003025B1 (ru) 1997-06-18 1998-06-15 Лечение диабета тиазолидиндионом и сульфонилмочевиной

Country Status (34)

Country Link
EP (3) EP0999845B1 (ru)
JP (1) JP2001523270A (ru)
KR (3) KR20080011356A (ru)
CN (1) CN1168451C (ru)
AP (1) AP1600A (ru)
AR (2) AR012996A1 (ru)
AT (1) ATE353654T1 (ru)
AU (1) AU8539298A (ru)
BG (2) BG109397A (ru)
BR (1) BR9810142A (ru)
CA (1) CA2294385C (ru)
CO (1) CO4940457A1 (ru)
CZ (1) CZ299310B6 (ru)
DE (1) DE69837089T2 (ru)
DZ (1) DZ2522A1 (ru)
EA (1) EA003025B1 (ru)
ES (1) ES2283064T3 (ru)
HK (1) HK1028200A1 (ru)
ID (1) ID24065A (ru)
IL (1) IL133137A (ru)
IN (1) IN189319B (ru)
MA (1) MA24571A1 (ru)
MY (1) MY125855A (ru)
NO (3) NO326263B1 (ru)
NZ (1) NZ501163A (ru)
OA (1) OA11510A (ru)
PE (1) PE108199A1 (ru)
PL (2) PL198018B1 (ru)
SK (1) SK286028B6 (ru)
TR (1) TR199903096T2 (ru)
TW (1) TW542717B (ru)
UA (1) UA67743C2 (ru)
UY (1) UY25048A1 (ru)
WO (1) WO1998057649A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
WO2001032184A2 (en) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
AU2004285354B2 (en) 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
RU2426530C2 (ru) 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1992000967A1 (fr) 1990-07-03 1992-01-23 Yamanouchi Pharmaceutical Co., Ltd. Compose biheterocyclique
US5334604A (en) 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
DE69231886T2 (de) 1991-04-11 2002-03-28 Pharmacia & Upjohn Co., Kalamazoo Thiazolidindionderivate, herstellung und anwendung
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
TW222626B (ru) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE151634T1 (de) * 1991-08-26 1997-05-15 Upjohn Co Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
EP0635007A1 (en) 1992-04-10 1995-01-25 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
TW542717B (en) 2003-07-21
EP1671637A2 (en) 2006-06-21
CN1168451C (zh) 2004-09-29
SK179199A3 (en) 2000-11-07
EP2266576A1 (en) 2010-12-29
AP9901717A0 (en) 1999-12-31
PE108199A1 (es) 2000-01-14
CZ299310B6 (cs) 2008-06-18
HK1028200A1 (en) 2001-02-09
BG109397A (bg) 2006-05-31
JP2001523270A (ja) 2001-11-20
MA24571A1 (fr) 1998-12-31
UA67743C2 (ru) 2004-07-15
NO2009002I1 (no) 2009-03-02
EP0999845A1 (en) 2000-05-17
SK286028B6 (sk) 2008-01-07
KR20010013840A (ko) 2001-02-26
ID24065A (id) 2000-07-06
EA003025B1 (ru) 2002-12-26
BR9810142A (pt) 2000-08-08
TR199903096T2 (xx) 2000-08-21
MY125855A (en) 2006-08-30
IL133137A (en) 2004-02-08
CO4940457A1 (es) 2000-07-24
IL133137A0 (en) 2001-03-19
DZ2522A1 (fr) 2003-02-01
NO326263B1 (no) 2008-10-27
NO996264L (no) 2000-02-17
IN189319B (ru) 2003-02-08
CA2294385A1 (en) 1998-12-23
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
UY25048A1 (es) 2000-09-29
PL337510A1 (en) 2000-08-28
AU8539298A (en) 1999-01-04
NZ501163A (en) 2002-02-01
ES2283064T3 (es) 2007-10-16
KR20070011651A (ko) 2007-01-24
AR012996A1 (es) 2000-11-22
CZ9904577A3 (en) 2001-05-16
KR20080011356A (ko) 2008-02-01
DE69837089T2 (de) 2007-06-21
CA2294385C (en) 2007-06-05
BG64817B1 (bg) 2006-05-31
PL198018B1 (pl) 2008-05-30
EP1671637A3 (en) 2007-12-19
AP1600A (en) 2006-04-28
NO996264D0 (no) 1999-12-17
EP0999845B1 (en) 2007-02-14
CN1260719A (zh) 2000-07-19
ATE353654T1 (de) 2007-03-15
OA11510A (en) 2004-02-03
BG104058A (en) 2000-10-31
AR008025A1 (es) 1999-12-09
DE69837089D1 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
EA200000139A1 (ru) Лечение диабета тиазолидиндионом, средством, стимулирующим секрецию инсулина, и дигуанидом
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
RU93053497A (ru) Новые пептиды-агонисты и их использование
EA200101089A1 (ru) Новый способ лечения
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
EA200000629A1 (ru) Стабилизированные растворы терипаратида
EA200300036A1 (ru) Комбинации ингибиторов дипептидилпептидазы iv и других антидиабетических агентов для лечения сахарного диабета
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
EA199800316A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
EA200000039A1 (ru) Лечение диабета тиазолидиндионом и сульфонилмочевиной
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
EA199800177A1 (ru) Способ снижения количества экзогенного инсулина, вводимого пациенту с инсулиннезависимым сахарным диабетом
HUP0002669A2 (hu) Diabetes kezelése dioxo-tiazolidinnel és szulfonil-karbamiddal
EA200000418A1 (ru) Применение тиазолидиндионов для лечения гипергликемии
ECSP982593A (es) Nuevo metodo de tratamiento vi
RU96120539A (ru) Способ снятия алкогольной зависимости и.в.кривопалова-москвина
EA200100539A1 (ru) Новый способ лечения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU